Genotyping cytochrome P450 3A5 using the light cycler

Annals of Clinical Biochemistry

Volumn 42, Issue 5, 2005, Pages 376-381

  Fredericks, Salim ^a   Moreton, Michelle ^a   MacPhee, Iain A M ^a   Mohamed, Maha ^a   Marlowe, Sharon ^b   Jorga, AnaMaria ^c   Johnston, Atholl ^c   Carter, Nicholas D ^a   Holt, David W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

BIOTRANSFORMATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA DENATURATION; DNA HYBRIDIZATION; DNA SEQUENCE; DRUG MONITORING; GENE MUTATION; GENOTYPE; HUMAN; PRIORITY JOURNAL; PSEUDOGENE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; DRUG MONITORING; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION;

EID: 25144485295     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563054889927     Document Type: Conference Paper

References (36)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23
2. Rendic S, Di CF. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580
3. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24
4. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59: 386-92
5. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260: 13-23
6. Watkins PB. Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete? Hepatology 1995; 22: 994-6
7. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-51
8. MacPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-9
9. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-94
10. Mustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-9
11. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13: 595-606
12. Andrews PA, Sen M, Chang RW. Racial variation in dosage requirements of tacrolimus. Lancet 1996; 348: 1446
13. MacPhee IA, Fredericks S, Mohamed M, et al. Tacrolimus Pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalised tacrolimus blood concentrations in Caucasians and South Asians. Transplantation 2005; 79: 499-502
14. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515-23
15. Undre N, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296-8
16. Clase C, Mahalati K, Kiberd B, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789-95
17. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neoral) during the first two weeks after renal transplantation. Transplantation 2001; 72: 1024-32
18. Fredericks S, Holt D, MacPhee IA. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am J Pharmacogenom 2003; 3: 291-301
19. Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005; 6: 37-47
20. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914-9
21. Goto M, Masuda S, Kiuchi T, et al. CYP3A5+ACo-1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14: 471-8
22. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121-32
23. Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a HuGE. Am J Epidemiol 2004; 160: 825-41
24. Spurdle AB, Goodwin B, Hodgson E, et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12: 355-66
25. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233-5
26. Liu TC, Lin SF, Chen TP, Chang JG. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep 2002; 9: 327-9
27. King BP, Leathart JB, Mutch E, Williams FM, Daly AK. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2004; 57: 664
28. Van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668-71
29. Zhu B, Chen GL, Chen XP, et al. Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population. Acta Pharmacol Sin 2002; 23: 567-72
30. Cooper TA, Mattox W. The regulation of splice-site selection, and its role in human disease. Am J Hum Genet 1997; 61: 259-66
31. Haufroid VF, Mourad MF, Van Kerckhove VF, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-54
32. Hesselink DA, van Schaik RH, van der Heiden I, van der Werf M, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54
33. Lay MJ, Wittwer CT. Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR. Clin Chem 1997; 43: 2262-7
34. von Ahsen N, Schutz E, Armstrong VW, Oellerich M. Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691A), and methylenetetrahydrofolate reductase (C677T) by real-time fluorescence PCR with the LightCycler. Clin Chem 1999; 45: 964-6
35. Mangasser-Stephan K, Tag C, Reiser A, Gressner AM. Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes. Clin Chem 1999; 45: 1875-8
36. Nauck M, Hoffmann MM, Wieland H, März W. Evaluation of the Apo E Genotyping Kit on the LightCycler. Clin Chem 2005; 46: 722-4